Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 204.e25-204.e33

  Chamie, Karim ^a   Klöpfer, Pia ^b   Bevan, Paul ^b   Störkel, Stephan ^c   Said, Jonathan ^a   Fall, Barbara ^b   Belldegrun, Arie S ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Wilex Biotechnology GmbH   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Adjuvant therapy; CAIX; Clinical trial; Prognostic biomarker; Renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84929275540     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.02.013     Document Type: Article

References (22)

1. Bui M.H., Seligson D., Han K.R., Pantuck A.J., Dorey F.J., Huang Y., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
2. Atkins M., Regan M., McDermott D., Mier J., Stanbridge E., Youmans A., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-3721.
3. Klatte T., Kabbinavar F.F., Zomorodian N., Belldegrun A.S., Pantuck A.J. Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma: interim results. J Urol 2007, 177:164.
4. Jensen H.K., Nordsmark M., Donskov F., Marcussen N., von der Maase H. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int 2008, 101(Suppl. 4):41-44.
5. Shah R.B., Amin A., Braun T., Redman B. High carbonic anhydrase (CA) IX protein tissue expression predicts response to interleukin (IL)-2 based therapy for advanced renal cell carcinoma patients. J Urol 2006, 175:235.
6. Leibovich B.C., Sheinin Y., Lohse C.M., Thompson R.H., Cheville J.C., Zavada J., et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-4764.
7. McDermott D., Ghebremichael M., Signoretti S., Margolin K., Clark J., Sosman J., et al. The high-dose aldesleukin (HD IL-2) "Select" trial in patients with metastatic renal cell carcinoma (mRCC). J Immunother 2010, 33:903-904.
8. May S., Hosmer D.W. Hosmer and Lemeshow type goodness-of-fit statistics for the Cox proportional hazards model. Advances in survival analysis: handbook of statistics 2004, vol 23:383-394. Elsevier, North-Holland, Amsterdam.
9. Kim H.L., Seligson D., Liu X., Janzen N., Bui M.H., Yu H., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004, 10:5464-5471.
10. Kroeger N., Seligson D.B., Klatte T., Rampersaud E.N., Birkhauser F.D., Rao P.N., et al. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol 2012, 61:888-895.
11. Vasselli J.R., Yang J.C., Linehan W.M., White D.E., Rosenberg S.A., Walther M.M. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol 2001, 166:68-72.
12. Pantuck A.J., Zisman A., Dorey F., Chao D.H., Han K.R., Said J., et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 2003, 97:2995-3002.
13. Zhang B.Y., Thompson R.H., Lohse C.M., Dronca R.S., Cheville J.C., Kwon E.D., et al. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int 2013, 111:1046-1053.
14. Oosterwijk E., Bander N.H., Divgi C.R., Welt S., Wakka J.C., Finn R.D., et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993, 11:738-750.
15. Steffens M.G., Boerman O.C., Oosterwijk-Wakka J.C., Oosterhof G.O., Witjes J.A., Koenders E.B., et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997, 15:1529-1537.
16. Steffens M.G., Boerman O.C., Oyen W.J., Kniest P.H., Witjes J.A., Oosterhof G.O., et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999, 59:1615-1619.
17. 18FFDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 2002, 23:229-236.
18. 111In: an intrapatient comparison. Clin Cancer Res 2003, 9:3953S-3960SS.
19. 124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007, 8:304-310.
20. Divgi C.R., Uzzo R.G., Gatsonis C., Bartz R., Treutner S., Yu J.Q., et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 2013, 31:187-194.
21. Muselaers C.H., Boerman O.C., Oosterwijk E., Langenhuijsen J.F., Oyen W.J., Mulders P.F. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013, 63:1101-1106.
22. Belldegrun AS, Chamie K, Klopfer P, Fall B, Bevan P, Storkel S, et al. A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence: results and implications for adjuvant clinical trials. ASCO. Chicago, IL; 2013.